Travere Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
TVTX$51.99+0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 202 and
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $93,035 | $58,535 |
| Marketable debt securities, at fair value | 229,761 | 312,166 |
| Accounts receivable, net | 80,134 | 27,116 |
| Inventory | 5,875 | 6,200 |
| Prepaid expenses and other current assets | 28,760 | 12,685 |
| Total current assets | 437,565 | 416,702 |
| Long-term inventory | 30,280 | 35,656 |
| Property and equipment, net | 4,022 | 5,336 |
| Operating lease right-of-use assets | 10,576 | 14,295 |
| Intangible assets, net | 113,868 | 103,974 |
| Other assets | 8,880 | 18,162 |
| Total assets | $605,191 | $594,125 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $24,800 | $23,534 |
| Accrued expenses | 126,035 | 86,028 |
| Convertible debt, current portion | — | 68,678 |
| Operating lease liabilities, current portion | 5,875 | 5,405 |
| Other current liabilities | 3,194 | 17,106 |
| Total current liabilities | 159,904 | 200,751 |
| Convertible debt, less current portion | 311,724 | 310,310 |
| Operating lease liabilities, less current portion | 11,134 | 17,191 |
| Other non-current liabilities | 7,601 | 6,796 |
| Total liabilities | 490,363 | 535,048 |
| Commitments and Contingencies (See Note 11) | ||
| Stockholders' Equity: | ||
| Preferred stock $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024 | — | — |
| Common stock $0.0001 par value; 200,000,000 shares authorized; 90,922,868 and 87,452,835 issued and outstanding as of December 31, 2025 and 2024, respectively | 9 | 9 |
| Additional paid-in capital | 1,588,721 | 1,506,315 |
| Accumulated deficit | (1,472,713) | (1,447,167) |
| Accumulated other comprehensive loss | (1,189) | (80) |
| Total stockholders' equity | 114,828 | 59,077 |
| Total liabilities and stockholders' equity | $605,191 | $594,125 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.